PURPOSE: Radiotherapy remains marginal in the treatment of renal cell carcinoma (RCC), due to radioresistance and risks of acute toxicity. However, recent data have shown that the m-TOR inhibitors could decrease the tumor resistance to ionizing radiation. At the same time, new highly conformal irradiation modalities may significantly improve the tolerance to radiation. METHODS: Here, we report the first case of concurrent use of mTOR antagonist, rapamycin and Helical Tomotherapy and its potential in critical organs sparing in a patient with retroperitoneal relapse from a RCC. He was treated with Everolimus, 10 mg/d and concurrent Helical Tomotherapy to the region of the recurrence (45 Gy, 1.8 Gy per fraction). RESULTS: Helical Tomotherapy allowed very sharp dose distributions around the target volumes, while sparing critical organs from useless radiation. No radiotherapy related acute toxicity was observed. At last follow-up (6 months later), the patient remains in partial remission at the irradiated region. CONCLUSIONS: While targeted agents might find applications for radiosensitizing purposes, this report highlights the potential of Helical Tomotherapy for reducing the doses delivered to the critical organs, thus improving tolerance to irradiation.
PURPOSE: Radiotherapy remains marginal in the treatment of renal cell carcinoma (RCC), due to radioresistance and risks of acute toxicity. However, recent data have shown that the m-TOR inhibitors could decrease the tumor resistance to ionizing radiation. At the same time, new highly conformal irradiation modalities may significantly improve the tolerance to radiation. METHODS: Here, we report the first case of concurrent use of mTOR antagonist, rapamycin and Helical Tomotherapy and its potential in critical organs sparing in a patient with retroperitoneal relapse from a RCC. He was treated with Everolimus, 10 mg/d and concurrent Helical Tomotherapy to the region of the recurrence (45 Gy, 1.8 Gy per fraction). RESULTS: Helical Tomotherapy allowed very sharp dose distributions around the target volumes, while sparing critical organs from useless radiation. No radiotherapy related acute toxicity was observed. At last follow-up (6 months later), the patient remains in partial remission at the irradiated region. CONCLUSIONS: While targeted agents might find applications for radiosensitizing purposes, this report highlights the potential of Helical Tomotherapy for reducing the doses delivered to the critical organs, thus improving tolerance to irradiation.
Authors: James D Murphy; Aaron C Spalding; Yash R Somnay; Sonja Markwart; Michael E Ray; Daniel A Hamstra Journal: Clin Cancer Res Date: 2009-01-15 Impact factor: 12.531
Authors: Cyrus Chargari; Francois Campana; Philippe Beuzeboc; Sofia Zefkili; Youlia M Kirova Journal: World J Gastroenterol Date: 2009-09-21 Impact factor: 5.742
Authors: Rupal S Bhatt; Daniel M Landis; Michael Zimmer; Joelle Torregrossa; Shaoyong Chen; Vikas P Sukhatme; Othon Iliopoulos; Steve Balk; Glenn J Bubley Journal: BJU Int Date: 2008-04-03 Impact factor: 5.588
Authors: Gisela Schieren; Edwin Bölke; Axel Scherer; Andreas Raffel; Peter Arne Gerber; Patric Kröpil; Matthias Schott; Jackson Hamilton; Anne Hayman; Wolfram Trudo Knoefel; Wilfried Budach; Christiane Matuschek Journal: Eur J Med Res Date: 2013-07-03 Impact factor: 2.175
Authors: Michal Grzmil; Yun Qin; Carina Schleuniger; Stephan Frank; Stefan Imobersteg; Alain Blanc; Martin Spillmann; Philipp Berger; Roger Schibli; Martin Behe Journal: Theranostics Date: 2020-08-29 Impact factor: 11.556
Authors: Michal Grzmil; Stefan Imobersteg; Alain Blanc; Stephan Frank; Roger Schibli; Martin P Béhé Journal: Pharmaceutics Date: 2021-12-15 Impact factor: 6.321